Trametinib is a Food and Drug Administration- and European Medicines Agency-approved MEK 1/2 inhibitor used to treat metastatic melanoma with B-Raf mutations and it entered phase II/III clinical trials in monotherapy for low-grade serous ovarian cancers (NCT02101788). The gene discussed is MAP2K1; the disease is ovarian serous adenocarcinoma.